← The Wire
LYELNasdaq
Lyell Immunopharma, Inc.
Pharmaceutical Preparations · DE · CIK 1806952
Advancing next-generation CAR T-cell therapies for patients with cancer, aiming for long-lasting clinical responses
$315M
Market cap
$12.75
Last close
+9.8%
1D
+6.5%
5D
200K
Volume
Price · last 39 sessions-38.5%
May 4L $11.61 · H $20.85Jun 29
99
Total filings
Jun 15, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 15, 202610-Q10-QMay 6, 20268-KResults of OperationsMay 6, 2026DEFA14ADEFA14AApr 24, 2026DEF 14ADEF 14AApr 24, 202610-K10-KMar 12, 20268-KResults of OperationsMar 12, 20268-KExecutive ChangeMar 9, 2026424B5424B5Dec 18, 20258-KCompany UpdateDec 8, 20258-KBylaw AmendmentDec 5, 202510-Q10-QNov 12, 20258-KResults of OperationsNov 12, 20258-KMaterial Agreement · Equity IssuanceNov 10, 20258-KExecutive ChangeNov 3, 20258-KExecutive ChangeSep 16, 202510-Q10-QAug 12, 20258-KResults of OperationsAug 12, 2025424B5424B5Jul 31, 20258-KMaterial Agreement · Equity IssuanceJul 25, 20258-KEquity IssuanceJun 26, 20258-KCompany UpdateJun 17, 20258-KExecutive ChangeJun 9, 20258-KSecurity-Holder RightsMay 28, 20258-KShareholder VoteMay 21, 202510-Q10-QMay 13, 20258-KResults of OperationsMay 13, 2025DEF 14ADEF 14AApr 21, 20258-KExecutive Change · Exit / Disposal CostsApr 1, 202510-K10-KMar 11, 20258-KResults of OperationsMar 11, 20258-KDelisting NoticeJan 24, 20258-K/ACompany UpdateJan 10, 20258-KCompany UpdateDec 10, 2024424B5424B5Dec 9, 20248-KExecutive ChangeNov 26, 202410-Q10-QNov 7, 20248-KResults of OperationsNov 7, 2024SC 13GSC 13GOct 31, 20248-KExecutive Change · Material AgreementOct 31, 20248-KMaterial Agreement · Equity IssuanceOct 24, 202410-Q10-QAug 7, 20248-KResults of OperationsAug 7, 20248-KReg FD Disclosure · Company UpdateJun 26, 20248-KShareholder VoteJun 14, 2024424B5424B5May 6, 202410-Q10-QMay 6, 20248-KResults of OperationsMay 6, 2024DEFA14ADEFA14AApr 22, 2024DEF 14ADEF 14AApr 22, 202410-K10-KFeb 28, 20248-KResults of OperationsFeb 28, 2024SC 13GSC 13GJan 29, 20248-KExecutive ChangeNov 20, 202310-Q10-QNov 7, 20238-KResults of OperationsNov 7, 20238-KReg FD DisclosureSep 11, 202310-Q10-QAug 8, 20238-KResults of OperationsAug 8, 20238-KShareholder VoteJun 21, 20238-KExecutive ChangeJun 6, 202310-Q10-QMay 4, 20238-KResults of OperationsMay 4, 2023DEFA14AFORM DEFA14AApr 27, 2023DEF 14ADEF 14AApr 27, 202310-K10-KFeb 28, 20238-KResults of OperationsFeb 28, 2023SC 13GSCHEDULE 13GFeb 9, 20238-KExecutive ChangeDec 16, 202210-Q10-QNov 8, 20228-KResults of OperationsNov 8, 20228-KAgreement TerminatedOct 24, 20228-KReg FD DisclosureOct 6, 202210-Q10-QAug 4, 20228-KResults of OperationsAug 4, 20228-KShareholder VoteJun 13, 202210-Q10-QMay 10, 20228-KResults of OperationsMay 10, 2022DEF 14ADEF 14AApr 28, 202210-K10-KMar 29, 2022
Insider Activity
◆ Cluster Buy · 2 insidersIn the 90 days to Mar 6, 2026: 2 insiders bought $25.0M · 4 sold $338K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 6, 2026 | Arch Venture Partners Ix Overage, L.P.TenPercentOwner | Buy | 488,090 | $25.61 | $12.5M |
| Mar 6, 2026 | Berns Paul LTenPercentOwner | Buy | 488,090 | $25.61 | $12.5M |
| Feb 11, 2026 | Seely LynnPresident and CEO | Sell | 7,455 | $23.39 | $174K |
| Feb 11, 2026 | Lee Gary K.Chief Scientific Officer | Sell | 1,671 | $23.39 | $39K |
| Feb 11, 2026 | Hill Stephen J.Chief Operating Officer | Sell | 1,236 | $23.39 | $29K |
| Feb 10, 2026 | Seely LynnPresident and CEO | Sell | 438 | $23.12 | $10K |
| Feb 10, 2026 | Bulis Veronica SanchezVP, Corporate Controller | Sell | 254 | $23.12 | $6K |
| Feb 10, 2026 | Lee Gary K.Chief Scientific Officer | Sell | 147 | $23.12 | $3K |
| Feb 10, 2026 | Hill Stephen J.Chief Operating Officer | Sell | 109 | $23.12 | $3K |
| Dec 30, 2025 | Bulis Veronica SanchezVP, Corporate Controller | Sell | 936 | $32.32 | $30K |
| Dec 24, 2025 | Bulis Veronica SanchezVP, Corporate Controller | Sell | 1,136 | $38.67 | $44K |
| Nov 10, 2025 | Seely LynnPresident and CEO | Sell | 412 | $16.11 | $7K |
| Nov 10, 2025 | Bulis Veronica SanchezVP, Corporate Controller | Sell | 239 | $16.10 | $4K |
| Nov 10, 2025 | Lee Gary K.Chief Scientific Officer | Sell | 138 | $16.16 | $2K |
| Nov 10, 2025 | Hill Stephen J.Chief Operating Officer | Sell | 95 | $16.12 | $2K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance